Lyra Therapeutics, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form 15 / Schedule TO; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$50M
Investors
24
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Lyra Therapeutics, Inc. is an entity organized in Delaware that filed a Form D with the SEC on April 30, 2026. The offering claims Securities Exchange Act of 1934. Lyra Therapeutics, Inc. reported $50,000,008 sold from 24 investors as of the Form D filed April 30, 2026. The Form D names Cantor Fitzgerald & Co. (CRD 134), associated with None; William Blair & Company, L.L.C. (CRD 1252), associated with None; H.C. Wainwright & Co., LLC (CRD 375), associated with None as recipients of sales compensation soliciting in all states. The issuer's address of record is 480 Arsenal Way, Watertown, MA 02472.
EDGAR Filing Data
Form 15 / Schedule TO — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Apr 30, 2026
Critical / warning
0 / 1
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
4
closed
Latest event Exchange act deregistration · Apr 30, 2026
SEC.govInvestor
- 1 filing event with values and deltas, latest 2026-04-30, and alerts on the next one
- 4 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2023-06-09: 2 related persons added and 3 removed against the filing of 2022-04-26; 12 now listed. The names are in the Terminal feed.
Harlan Waksal, M.D.
Executive Officer, Director · Watertown, MA
Maria Palasis, Ph.D.
Executive Officer, Director · Watertown, MA
Jason Cavalier
Executive Officer · Watertown, MA
Michael Altman
Director · Watertown, MA
Edward Anderson
Director · Watertown, MA
C. Ann Merrifield
Director · Watertown, MA
Konstantin Ann Poukalov
Director · Watertown, MA
W. Bradford Smith
Director · Watertown, MA
Nancy Bradford Snyderman, M.D., FACS
Director · Watertown, MA
James R. Tobin
Director · Watertown, MA
John R. Bishop, Ph.D.
Executive Officer · Watertown, MA
Richard R. Nieman, M.D.
Executive Officer · Watertown, MA
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Cantor Fitzgerald & Co.CRD 134 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states
William Blair & Company, L.L.C.CRD 1252 on BrokerCheck
Associated broker-dealer: None · Chicago, IL · Soliciting in all states
H.C. Wainwright & Co., LLCCRD 375 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states
Questions About Lyra Therapeutics, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Lyra Therapeutics, Inc.?
Lyra Therapeutics, Inc. is an issuer that filed a Form D with the SEC on April 30, 2026. The filing claims Securities Exchange Act of 1934.
Is Lyra Therapeutics, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Lyra Therapeutics, Inc. filed a Form D with the SEC on April 30, 2026 claiming Securities Exchange Act of 1934. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $50,000,008 sold to 24 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Lyra Therapeutics, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Lyra Therapeutics, Inc. claimed Securities Exchange Act of 1934 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Lyra Therapeutics, Inc. raised?
Lyra Therapeutics, Inc. reported $50,000,008 sold from 24 investors as of the Form D filed April 30, 2026.
Who is selling Lyra Therapeutics, Inc. and how are they paid?
The Form D names Cantor Fitzgerald & Co. (CRD 134), associated with None; William Blair & Company, L.L.C. (CRD 1252), associated with None; H.C. Wainwright & Co., LLC (CRD 375), associated with None as recipients of sales compensation soliciting in all states.
Who is behind Lyra Therapeutics, Inc.?
The Form D lists 12 related persons: Harlan Waksal, M.D., executive officer, director; Maria Palasis, Ph.D., executive officer, director; Jason Cavalier, executive officer; Michael Altman, director; Edward Anderson, director; C. Ann Merrifield, director; Konstantin Ann Poukalov, director; W. Bradford Smith, director, and 4 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Lyra Therapeutics, Inc. located?
The issuer's address on its SEC filings is 480 Arsenal Way, Watertown, MA 02472. Its phone number of record is 617-373-4600. It is organized under the laws of Delaware.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.